Ocugen has raised $7.5 million in a series B round as it fixes its sights on advancing a trio of eye disease treatments into clinical trials.

Mersana Therapeutics is capitalizing on a buoyant period with a filing for a $75 million IPO to advance its antibody-drug conjugates (ADCs) for cancer through…

Deciphera Pharmaceuticals will head to ASCO this week with a spring in its step after raising $52 million in a third-round financing.

The CEO of Akari Therapeutics has quit amid a probe into the release of phase 2 data and a related analyst report.

The U.K. has been closing the gap on life sciences sectors in Boston and San Francisco, but uncertainty caused by Brexit may undermine those efforts, said the…

TP Therapeutics has the funds on hand to take its drug for resistant cancer through the next stages of clinical development after raising $45 million in a…

G1 Therapeutics thinks it has a winner on its hands with CDK4/6 inhibitor trilaciclib and is embarking on an initial public offering to give it the resources…

AstraZeneca's European pharma VP is reported to be on "gardening leave" after his employer sues for breaching his employment contract.

Singapore’s state-owned investment firm Temasek and Chinese internet tycoon Jack Ma-backed Yunfeng Capital have led a $75 million Series B into WuXi NextCODE.

Financials